Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Negative equity NBB
More debt than assets in 4 of the last 4 fiscal years.
-
Two loss years in a row NBB
Negative result in 2024 and 2025.
-
Tight liquidity NBB
Cash and receivables cover 12 % of short-term debt in 2025; threshold 65 %.
Financials
Financial year 2025
CELYNTRA THERAPEUTICS from Mont-Saint-Guibert, company number BE0737829015, closed financial year 2025 with a result of € -3.1 million after tax. For that financial year CELYNTRA THERAPEUTICS recorded a gross margin of € 560,992 and equity of € -9.6 million. Compared with financial year 2024, the result moved from € -6.4 million to € -3.1 million. The company made a loss. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on June 10, 2026.
€ -9.6 million
▼ € 2.7 million vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -3.1 million
▲ 52 % less loss than in 2024
Profit after tax over the fiscal year.
€ 445,046
▲ 207% vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -10.4 million.
People and assets in 2025
12.7
Average over the fiscal year, from the social balance sheet.
€ 1.3 million
▲ 12% vs 2024
€ 100,200 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 6.8 million
▲ 62% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 191,496
▲ 15% vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € -99,228 | € -837,405 | € -3,849,515 | € 560,992 | ▲ € 4.4 million |
| Profit after taxes | € -123,119 | € -951,235 | € -6,394,036 | € -3,065,141 | ▲ € 3.3 million |
| Equity | € -1,747,700 | € -598,935 | € -6,852,391 | € -9,597,948 | ▼ € 2.7 million |
| Total debts | € 1,852,691 | € 3,345,624 | € 14,779,303 | € 17,642,013 | ▲ 19% |
| Cash | € 57,602 | € 2,097,313 | € 144,794 | € 445,046 | ▲ 207% |
| Retained profit | € -1,809,200 | € -951,235 | € -7,345,271 | € -10,410,412 | ▼ € 3.1 million |
| Balance sheet total | € 104,991 | € 2,746,689 | € 7,926,911 | € 8,199,065 | ▲ 3% |
| Employees (FTE) | - | - | 12.7 | 12.7 |
Key figures of CELYNTRA THERAPEUTICS, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to CELYNTRA THERAPEUTICS?
What happened at CELYNTRA THERAPEUTICS in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Jason Conner stepped down as director. NBB
- New annual accounts for financial year 2025: loss of € 3.1 million. Source: NBB ↗
- Jason Conner became a director. NBB
- New establishment in Mont-Saint-Guibert. KBO
- Start of the company according to the CBE. KBO
In short
From € 123,119 loss in 2022 to € 3.1 million loss in 2025.
On average € 44,200 of value added per employee in 2025.
A new publication or filing at CELYNTRA THERAPEUTICS? We notify you, reason included.
Follow CELYNTRA THERAPEUTICSDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The stake of Ncardia Holding comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
CELYNTRA THERAPEUTICSThe shares are held by Ncardia Holding (0%).
Directors
According to the 2025 annual accounts
since 2026 · until 2027
Shareholders
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Rue Edouard Belin 2
1435 Mont-Saint-Guibert
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 2 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0737.829.015
- VAT number
- BE 0737.829.015
- Registered office
- Rue Edouard Belin 2, 1435 Mont-Saint-Guibert
- Names & denominations
- CELYNTRA THERAPEUTICS
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 19 November 2019
- Peppol
- Active · Active since 27 Nov 2025
- Activities · NACE
Groothandel in farmaceutische en medische artikelen